Related Experiment Video
Updated: Jul 11, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
[Alzheimer Disease].
1Hôpital Notre-Dame, Service de gériatrie, 1560, Sherbrooke Est, Montréal, (Québec) H2L 2M1. fadi-massoud@videotron.ca
Canadian Family Physician Medecin De Famille Canadien
|September 18, 2007
Summary
Managing vascular risk factors is crucial for Alzheimer disease (AD) patients. Memantine offers an effective and well-tolerated treatment option for moderate to severe AD.
Area of Science:
- Neurology
- Pharmacology
Context:
- Alzheimer disease (AD) is the leading cause of dementia.
- Recent advancements in AD pharmacotherapy are emerging.
Purpose:
- To review two key advancements in Alzheimer disease management: vascular prevention strategies and the novel drug memantine.
- To assess the role of vascular disease in AD pathogenesis and the efficacy of memantine.
Summary:
- Vascular disease is increasingly recognized as a significant factor in Alzheimer disease (AD) pathophysiology.
- Memantine, a non-competitive NMDA receptor antagonist, demonstrates a favorable efficacy and safety profile for moderate to severe AD.
- Level I and II evidence supports the conclusions presented.
Impact:
- Integrating vascular risk factor management into AD care is recommended.
- Memantine presents a valuable new therapeutic option for patients with moderate to severe Alzheimer disease, improving treatment outcomes.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.